Class Action Lawsuit Filed Against Hims & Hers Health, Inc. (HIMS) - Recover Losses - Contact Levi & Korsinsky Before August 25, 2025
A class action lawsuit has been filed against Hims & Hers Health, Inc. (HIMS) alleging securities fraud between April 29, 2025, and June 23, 2025. The lawsuit claims Hims engaged in deceptive promotion of "knockoff" versions of Wegovy, risking termination of its collaboration with Novo Nordisk. Shareholders who suffered losses during this period are encouraged to contact Levi & Korsinsky, LLP by August 25, 2025, to learn about their rights.
Hims & Hers Health, Inc. Class A Trade Ideas — SIX:HIMS.USD
This article compiles various trade ideas and analyses for Hims & Hers Health, Inc. (HIMS) stock, covering different perspectives from bullish long-term outlooks to cautious short-term setups. Key themes include the company's strong June performance, expansion into new markets and treatments like peptides and GLP-1s, and strategic partnerships, alongside discussions on insider selling, potential dilution from convertible notes, and the challenges of achieving sustained profitability.
HIMS Class Action Alert: Kessler Topaz Meltzer & Check, LLP Reminds Hims & Hers Health, Inc. (HIMS) Shareholders of Securities Fraud Class Action Lawsuit Deadline
Kessler Topaz Meltzer & Check, LLP has issued a reminder to shareholders of Hims & Hers Health, Inc. (HIMS) about an ongoing securities fraud class action lawsuit. Investors who purchased HIMS securities between April 29, 2025, and June 23, 2025, are affected, and the lead plaintiff deadline is August 25, 2025. The lawsuit alleges that Hims & Hers misrepresented its business by deceptively promoting and selling "knockoff versions of Wegovy," leading to a substantial risk of terminated collaboration with Novo Nordisk.
Lost Money on Hims & Hers Health, Inc. (HIMS)? Join Class Action Before August 25, 2025 - Contact Levi & Korsinsky
Levi & Korsinsky, LLP has filed a class action securities lawsuit against Hims & Hers Health, Inc. (NYSE:HIMS) for alleged securities fraud between April 29, 2025, and June 23, 2025. The lawsuit claims that Hims engaged in deceptive promotion of "knockoff" versions of Wegovy®, posing risks to patient safety and potentially jeopardizing its collaboration with Novo Nordisk. Shareholders who incurred losses during this period are encouraged to contact Levi & Korsinsky to learn about their rights to participate in the recovery effort before August 25, 2025.
Trading the Move, Not the Narrative: (HIMS) Edition
This article provides an AI-generated analysis for Hims & Hers Health Inc. (NASDAQ: HIMS), highlighting weak near-term sentiment but mid-term strength within a long-term weak bias. It details three distinct institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis also includes multi-timeframe signal analysis, showing support and resistance levels for various time horizons.
Hims & Hers Health, Inc. Class A Actuals & Estimates (NYSE:HIMS)
This article provides an overview of Hims & Hers Health, Inc. (NYSE:HIMS) stock performance, financial actuals, and analyst estimates. It covers the current stock price, historical highs and lows, market capitalization, volatility, and upcoming earnings dates. The content also includes frequently asked questions about investing in HIMS stock.
Price to book forward of Hims & Hers Health, Inc. Class A – XETR:82W
This article provides access to the "Price to book forward" financial metric for Hims & Hers Health, Inc. Class A (XETR:82W) on TradingView. It indicates that the market was closed at the time of publication and there were no trades. The content primarily directs users to various sections of the TradingView platform for financial data, community, and other products related to this stock.
Hims & Hers CMO Patrick Carroll sells $830,410 in stock
Patrick Carroll, CMO of Hims & Hers Health, Inc., sold 23,726 shares of company stock for $830,410 on June 18, 2026. This transaction reduced his direct holdings to 181,861 shares of Class A Common Stock. The sale follows other company developments, including a raised price target from Barclays and the appointment of a new Chief Medical Officer, Dr. Anant Vinjamoori, after an annual meeting where nine directors were elected.
Hims & Hers CMO Patrick Carroll sells $830,410 in stock
Patrick Harrison Carroll, CMO of Hims & Hers Health, Inc. (NASDAQ:HIMS), sold 23,726 shares of company stock for $830,410 at $35.0 per share on June 18, 2026. After this transaction, he directly holds 181,861 shares. This sale follows other recent company updates, including an increased price target from Barclays and the appointment of a new Chief Medical Officer, Dr. Anant Vinjamoori.
[Form 4] Hims & Hers Health, Inc. Insider Trading Activity
Hims & Hers Health, Inc. CFO Oluyemi Okupe reported stock option exercises and sales of common shares under a pre-arranged Rule 10b5-1 trading plan. Okupe exercised 6,376 shares of Class A common stock at $5.01 per share and sold 18,197 shares at an average price of $34.0285 per share. Following these transactions, Okupe holds 284,321 direct shares and 7,853 indirect shares of Class A common stock.
Hims & Hers CFO Oluyemi Okupe sells $619,216 in shares By Investing.com
Hims & Hers Health, Inc.'s CFO, Oluyemi Okupe, sold 18,197 shares of Class A Common Stock for $619,216 on June 22, 2026, after exercising stock options. The sale was executed under a Rule 10b5-1 trading plan. This transaction follows other company developments, including a raised price target from Barclays and an upcoming regulatory meeting regarding compounded peptides.
Hims & Hers (NYSE: HIMS) CMO sells 23,726 shares, retains 181,861
Hims & Hers Health, Inc.'s Chief Medical Officer, Patrick Harrison, sold 23,726 shares of Class A Common Stock at $35.00 per share in an open-market transaction. Following this sale, Harrison still directly holds 181,861 shares of the company. The transaction is categorized as a routine liquidity event rather than a significant change in his equity exposure.
Hims & Hers Health, Inc. Class A Trade Ideas — BIVA:HIMS
This article compiles several trading ideas and analyses for Hims & Hers Health, Inc. (HIMS) from various traders on TradingView. It discusses potential technical patterns like inverse head and shoulders and mini head and shoulders, along with support and resistance levels, price targets, and risk considerations for both long and short positions. Many analyses also reference earnings reports, CPI data, and overall market movements impacting HIMS stock.
Hims & Hers PAO Irene Becklund sells $370,518 in stock By Investing.com
Irene Becklund, Principal Accounting Officer at Hims & Hers Health, Inc. (NASDAQ:HIMS), sold shares totaling $370,518 in two transactions on June 16 and June 17, 2026. These sales were part of a pre-arranged trading plan and followed the vesting of Restricted Stock Units. The company's stock is currently trading at $31.89, with InvestingPro analysis indicating it may be overvalued.
Hims & Hers (NYSE: HIMS) CEO exercises RSUs and withholds shares for taxes
Hims & Hers Health CEO Andrew Dudum exercised 154,991 Restricted Stock Units (RSUs) on June 15, 2026. To cover tax obligations related to this vesting, 85,632 shares were withheld by the company at $30.17 per share. Following these transactions, Dudum directly holds 957,043 shares of Class A Common Stock, with significant additional indirect holdings through family trusts.
HIMS (NYSE) Form 144: 12,500 and 11,226 vested Class A shares listed
Hims & Hers Health, Inc. (HIMS) has filed a Form 144 indicating proposed sales related to the vesting of Class A shares. The filing specifies two vesting events: 12,500 shares on March 15, 2026, and 11,226 shares on June 15, 2026. Fidelity Brokerage Services LLC is named as the broker-dealer, with sales expected to occur on the NYSE.
Hims & Hers PAO Irene Becklund sells $370,518 in stock
Hims & Hers Health, Inc.'s Principal Accounting Officer, Irene Becklund, sold $370,518 worth of Class A Common Stock across two transactions in mid-June. These sales were executed under a pre-arranged trading plan, following the vesting of Restricted Stock Units. After these transactions and tax withholdings, Becklund directly holds 6,790 shares.
Hims & Hers CTO Mohamed Elshenawy sells $946,260 in stock
Hims & Hers Health, Inc. CTO Mohamed Elshenawy sold 30,040 shares of Class A Common Stock for $946,260 on June 17, 2026, as part of a Rule 10b5-1 trading plan. He also disposed of 151,534 shares worth $4,571,780 to cover tax obligations related to vested Restricted Stock Units (RSUs) and acquired 282,597 shares through RSU vesting. This news comes amidst other company developments, including analyst upgrades and a new CMO appointment.
Hims & Hers COO Michael Chi sells $441,850 in company stock
Michael Chi, COO of Hims & Hers Health, Inc., sold 14,027 shares of company stock worth $441,850 on June 17, 2026, under a pre-arranged trading plan. This sale followed his acquisition of 86,264 shares through RSU vesting, with a portion withheld for taxes. The company has also seen recent analyst price target adjustments and strategic leadership changes.
Hims & Hers Health (HIMS) CTO exercises awards and sells 30,040 shares
Hims & Hers Health's CTO, Mohamed Elshenawy, exercised derivative awards for 282,597 shares and sold 30,040 shares at $31.50 each under a pre-arranged Rule 10b5-1 trading plan. The company also withheld 151,534 shares to cover tax obligations from RSU vesting. Following these transactions, Elshenawy directly holds 101,023 shares of Class A Common Stock.
Hims & Hers PAO Irene Becklund sells $370,518 in stock
Irene Becklund, the Principal Accounting Officer at Hims & Hers Health, Inc., sold $370,518 worth of company stock in two transactions on June 16 and 17, 2026, under a pre-arranged trading plan. These sales occurred after the vesting of Restricted Stock Units and tax withholding, leaving Becklund with 6,790 direct shares. The article also mentions recent analyst updates and corporate developments for Hims & Hers Health.
[Form 4] Hims & Hers Health, Inc. Insider Trading Activity
Hims & Hers Health, Inc.'s Chief Legal Officer, Soleil Boughton, reported a stock compensation activity. On June 15, 2026, 42,261 Class A Common Stock shares were acquired through RSU conversion, while 23,315 shares were withheld for tax obligations. Following these transactions, Boughton directly holds 341,629 Class A shares, indicating a continued stake in the company rather than a market sale.
Hims & Hers (HIMS) exec nets shares after 32,919 RSU conversion
Hims & Hers Health, Inc. Chief Policy Officer Deborah M. Autor converted 32,919 Restricted Stock Units (RSUs) into Class A Common shares on June 15, 2026. After withholding 15,396 shares for tax obligations at $30.17 per share, she now directly holds 48,961 Class A Common shares. Autor also holds 460,873 additional RSUs with a four-year service-based vesting schedule.
Hims & Hers (HIMS) CMO logs RSU vesting and tax share withholding
Hims & Hers Health Chief Medical Officer Patrick Harrison reported the vesting of 25,926 Restricted Stock Units (RSUs) on June 15, 2026. To cover tax obligations, 8,310 shares were withheld by the company, meaning no open-market sale occurred. Following these transactions, Harrison directly holds 213,897 shares of Class A Common Stock, indicating routine equity compensation activity.
Hims & Hers CTO Mohamed Elshenawy sells $946,260 in stock
Hims & Hers CTO Mohamed Elshenawy sold $946,260 worth of Class A Common Stock on June 17, 2026, as part of a Rule 10b5-1 trading plan. He also disposed of shares to cover tax obligations from RSU vesting and acquired new shares through RSU vesting on June 15, 2026. This comes amidst analyst price target increases, expansion into preventive health, and recent corporate governance news for Hims & Hers.
Hims & Hers (NYSE: HIMS) COO sells 14,027 shares, holds 432,124
Hims & Hers Health, Inc. COO Michael Chi sold 14,027 shares of Class A Common Stock at $31.50 per share under a pre-arranged Rule 10b5-1 trading plan. This transaction followed the exercise of 86,264 RSU awards and the withholding of 47,699 shares to cover tax obligations. After these routine transactions, Chi directly holds 432,124 shares, indicating a substantial remaining equity position.
Hims & Hers (NYSE: HIMS) CFO exercises RSUs as shares withheld for tax
Hims & Hers Health, Inc.'s CFO, Oluyemi Okupe, recently exercised 71,616 Restricted Stock Units (RSUs) which converted into Class A Common Stock. To cover tax withholding obligations, 39,541 shares were withheld by the company at $30.17 per share. Following these transactions, Okupe directly holds 296,142 shares and indirectly holds 7,853 shares through a separate trust.
Hims & Hers COO Michael Chi sells $441,850 in company stock
Michael Chi, COO of Hims & Hers Health, Inc. (NASDAQ:HIMS), sold 14,027 shares of company stock for $441,850 on June 17, 2026, under a Rule 10b5-1 trading plan. This transaction followed his acquisition of 86,264 shares through RSU vesting, with a portion withheld for tax obligations. Hims & Hers stock has experienced significant volatility, being down 46% over the past year, and analysts have recently updated their ratings and price targets, while the company continues to expand its health offerings and leadership team.
Hims Holdings (HIMS) Form 144: Director lists proposed sale of Class A shares
A Hims Holdings (HIMS) Form 144 filing indicates proposed sales of Class A shares by a director. The filing details restricted stock vesting events in March and June 2026, and two proposed sales by Irene Becklund totaling 5,529 and 7,573 shares, with associated proceeds of $136,511.01 and $229,083.25, respectively. This transparency allows investors to track
HIMS (NYSE) Form 144 shows insiders propose selling 14,027 and 97,289 Class A shares
Hims & Hers Health, Inc. (HIMS) filed a Form 144 indicating proposed sales of Class A shares by an affiliate, Fidelity Brokerage Services LLC, and an individual, Michael Y. Chi. The filing details 14,027 shares associated with Fidelity and 97,289 shares linked to Michael Y. Chi, both stemming from Restricted Stock Vesting. These disclosures are procedural and do not specify the exact sale mechanics.
Insider sells 5,529 Class A shares at HIMS (HIMS) via Fidelity
An insider at Hims & Hers Health, Inc. (HIMS) has filed a Form 144 notice indicating proposed sales of Class A shares through Fidelity Brokerage Services. The filing details a reported sale by Irene Becklund of 5,529 Class A shares on March 17, 2026, for $136,511.01. The notice also lists upcoming restricted stock vesting events for Class A shares on June 15, 2025, September 15, 2025, and March 15, 2026.
Executive at Hims & Hers (HIMS) receives 3,656 shares from RSU vesting
Deborah M. Autor, Chief Policy Officer at Hims & Hers Health, Inc., received 3,656 shares of Class A Common Stock from the vesting of restricted stock units (RSUs) on June 11, 2026, at no cost. This transaction is considered a routine equity compensation event, increasing her direct holdings to 31,438 shares. No shares were sold in connection with this vesting.
Hims & Hers (NYSE: HIMS) director converts 3,656 RSUs into common shares
Hims & Hers Health director Kare Schultz converted 3,656 Restricted Stock Units (RSUs) into an equal number of Class A common shares on June 11, 2026, at an exercise price of $0.00 per share. This derivative exercise increased Schultz's direct holdings to 19,397 shares of Class A common stock. The RSUs vested subject to continuous service and were set to vest on the earlier of the 2026 annual meeting or June 15, 2026.
Hims & Hers (NYSE: HIMS) director exercises RSUs for 14,343 shares
Hims & Hers Health, Inc. director Christopher D. Payne exercised restricted stock unit awards, converting them into 14,343 shares of Class A Common Stock in June 2026 at $0.00 per share. These were compensation-related transactions, not open-market purchases. Following these exercises, Payne directly holds 34,318 shares and indirectly holds 110,000 shares through a family trust.
Director at Hims & Hers (NYSE: HIMS) gains 13,696 shares through RSU exercises
Hims & Hers Health, Inc. director Manuel Anja acquired a total of 13,696 shares of Class A Common Stock through RSU exercises on June 11 and June 15, 2026, at a stated price of $0.0000 per share. These transactions increased his direct ownership to 38,671 shares. The RSUs represent a contingent right to receive Class A Common Stock, subject to continuous service and a service-based vesting schedule through 2027.
Hims & Hers Health (HIMS) director exercises 3,656 RSUs into common stock
Hims & Hers Health director Andrea G Perez Garcia exercised 3,656 Restricted Stock Units (RSUs) into an equal number of Class A Common Stock shares at no cost on June 11, 2026. This compensation-related transaction increased her direct holdings to 83,822 shares of Class A Common Stock. The RSUs vest upon continuous service, specifically on the earlier of the 2026 annual meeting or June 15, 2026.
Hims & Hers Health, Inc. Class A Trade Ideas — XETR:82W
This article compiles various trade ideas and analyst perspectives on Hims & Hers Health, Inc. (HIMS) following its partnership agreement with Novo Nordisk. Analysts highlight the removal of legal overhangs and the potential for a short squeeze due to high short interest. The deal is seen as a significant strategic shift for Hims & Hers, enabling it to distribute branded GLP-1 weight-loss drugs and potentially leading to substantial growth despite some lingering caution from Wall Street.
Hims & Hers Health, Inc. Class A Trade Ideas — XETR:82W
This page on TradingView aggregates various trade ideas and analyses for Hims & Hers Health, Inc. (XETR:82W, NYSE:HIMS) from different traders. The sentiment ranges from bullish, identifying potential breakouts and uptrends based on technical
Hims & Hers Health, Inc. Class A Trade Ideas — XETR:82W
This article compiles several trade ideas and analyses for Hims & Hers Health, Inc. (HIMS) from various traders on TradingView. The perspectives range from bearish setups anticipating a pullback due to recent news, particularly the terminated partnership with Novo Nordisk, to bullish outlooks based on technical patterns like cup-and-handle formations and strong fundamental growth in telemedicine. Traders provide specific entry points, targets, and stop-loss levels, reflecting diverse strategies and market sentiments for HIMS.
Hims & Hers Health, Inc. Class A Trade Ideas — XETR:82W
This article aggregates various trading ideas for Hims & Hers Health, Inc. (XETR:82W, NYSE:HIMS) from different traders on TradingView. The perspectives are mixed, with several traders predicting bullish movements based on technical analysis, market momentum, and strategic expansions, while others remain bearish due to institutional selling pressure, legal concerns, and high valuations. The analyses include specific trade setups, risk factors, and price targets using tools like options trading, Fibonacci levels, and various chart patterns, highlighting the diverse sentiment surrounding the stock.
Enterprise value to EBITDA ratio of Hims & Hers Health, Inc. Class A – XETR:82W
This article provides financial information for Hims & Hers Health, Inc. Class A, traded on XETR under the symbol 82W. It specifically details the enterprise value to EBITDA ratio for the company. The page also lists various services and resources offered by TradingView, the platform on which this data is presented.
Hims & Hers Health, Inc. Class A Trade Ideas — XETR:82W
This article compiles various trade ideas and technical analyses for Hims & Hers Health, Inc. Class A (XETR:82W, NYSE:HIMS). Traders discuss potential price movements based on support and resistance levels, trendlines, volume profiles, and RSI, with many anticipating upward movement towards targets like $60, $73, or even $100, citing strong fundamentals, subscriber growth, and GLP-1 program momentum. However, some acknowledge short-term bearish possibilities and emphasize risk management around key support levels.
Price-Driven Insight from (HIMS) for Rule-Based Strategy
This article provides a price-driven insight for Hims & Hers Health Inc. (NASDAQ: HIMS), highlighting strong near and mid-term sentiment but a weak long-term outlook. It details three AI-generated trading strategies (Position, Momentum Breakout, and Risk Hedging) with specific entry, target, and stop-loss levels. The analysis also includes multi-timeframe signal analysis for support and resistance levels.
Hims & Hers Gains 5% on Insider Buying
Hims & Hers Health, Inc. (HIMS) saw its stock rise by 5.07% intraday following a significant purchase of Class A common stock by director David B. Wells, totaling $1.17 million. This insider buying occurred after a period of stock decline for Hims & Hers and two weeks after the company reported Q1 results, which included a strategic shift and raised full-year 2026 revenue guidance.
Director David B. Wells increases Hims & Hers (HIMS) stake with 48,400-share buy
Hims & Hers Health, Inc. director David B. Wells purchased 48,400 shares of Class A Common Stock on May 26, 2026, at an average price of $24.235 per share, increasing his direct holdings to 224,417 shares. This open-market transaction, detailed in a Form 4 filing, signals a positive sentiment from the insider. The total value of the buy was approximately $1.17 million.
Hims & Hers (HIMS) CMO-director gets 435 RSUs instead of $10K cash retainer
Hims & Hers Health, Inc. Chief Medical Officer and director Patrick Harrison was granted 435 Restricted Stock Units (RSUs) as part of his board compensation, in lieu of a $10,000 cash retainer for the first quarter of 2026. These RSUs will convert into Class A Common Stock upon vesting on the company's next quarterly vesting date. This transaction aligns his compensation with the company's equity performance.
(HIMS) Price Dynamics and Execution-Aware Positioning
This article from Stock Traders Daily discusses Hims & Hers Health Inc. (NASDAQ: HIMS), highlighting weak sentiment across all time horizons. It identifies a mid-channel oscillation pattern and presents an exceptional short setup targeting significant downside. The report provides various trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels derived from AI models for different risk profiles.
Hims & Hers Health, Inc. Class A Trade Ideas — BMV:HIMS
This article compiles various trading ideas for Hims & Hers Health, Inc. (HIMS) from different traders on TradingView. The ideas include both bullish breakout setups and bearish short-trade setups, utilizing technical analysis such as symmetrical triangles, rising wedges, and support/resistance levels. Each trade idea provides detailed entry zones, stop-loss levels, take-profit targets, and risk-reward ratios, alongside strategies for volume confirmation and profit booking.
Hims & Hers (HIMS) director Christopher Payne awarded 647 RSUs for Q1 2026 fees
Hims & Hers Health, Inc. director Christopher D. Payne was granted 647 Restricted Stock Units (RSUs) as equity compensation, replacing $14,875 in cash fees for the first quarter of 2026. This award was made under the company’s Director Compensation Policy at a grant price of $22.98 per RSU. The RSUs will vest in full on the company's next quarterly vesting date, with each RSU representing one share of Class A common stock.
Hims & Hers Health (HIMS) director awarded 957 RSUs for Q1 fees
Hims & Hers Health, Inc. director David B. Wells was granted 957 restricted stock units (RSUs) as part of his 2026 first-quarter board compensation. These RSUs were issued in lieu of $22,000 in cash fees, calculated using a grant price of $22.98 per unit. The RSUs will vest in full on the company’s next quarterly vesting date, and following this grant, Wells holds 957 RSUs directly.
